ConductScience.org, home

Comparison · NCT00809146-b129eaea

IM Midazolam vs IV Lorazepam: Number of Subjects With IM Injection-site Complications

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. IM Midazolam vs IV Lorazepam: Number of Subjects With IM Injection-site Complications. Trial comparisons, record NCT00809146-b129eaea. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00809146-b129eaea

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.008930.003480.0227wilson
Risk in group 20.004490.001230.0162wilson
Risk difference, group 1 minus group 20.00443-0.008510.0186newcombe hybrid score
Risk ratio, group 1 over group 21.990.36610.8log
Odds ratio, group 1 over group 220.36411log
Number needed to treat, for one more participant with the outcome on IM Midazolam than on IV Lorazepam226from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1IM MidazolamSubjects in whom the study IM autoinjector contained active treatment with midazolam4448OG000
Group 2IV LorazepamSubjects in whom the study IV infusion contained active treatment with lorazepam2445OG001

Outcome

Type
SECONDARY
Title
Number of Subjects With IM Injection-site Complications
Description
IM injection site complications are defined as any symptoms or signs of injury or reaction at the site of the study IM injection requiring treatment. This includes extensive hematoma requiring treatment (decompression, pressure dressings, or discontinuation of anticoagulant or antithrombotic medications). Treatment does not include imaging without other interventions. This definition also includes wound infection requiring antibiotic therapy, retained foreign bodies requiring exploration and removal, or other similar wound problems.
Time frame
participants were followed for the duration of hospital stay, an average of 6 days
Population

Source ClinicalTrials.gov

Trial

Title
Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications
NCT number
NCT00809146
Phases
PHASE3
Conditions
Status Epilepticus
Interventions
Intramuscular route of active treatment, Intravenous route of active treatment
Lead sponsor
Robert Silbergleit
Results first posted
2012-04-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00809146-b129eaea